What BPC-157 tendon studies measured
A 2003 study of BPC-157 reported findings from an Achilles tendon injury model in rats and a separate experiment with cultured tendon cells. A 2011 study examined tissue outgrowth and cell behavior in different laboratory models. Each finding is listed next to its species, model, and endpoint, so you can see exactly what was studied.
One paper, two models
Staresinic et al. (2003) reported work in two settings:
- In vivo: rats with a transected (surgically cut) Achilles tendon
- In vitro: tendocytes, which are tendon cells, grown in culture
Because both models come from one research group, one paper, and one publication, they share authors, methods choices, and peer review. A tissue-level result and a cell-level result in the same report can be consistent with each other. That still makes them a single source, not two independent confirmations.
Evidence table
| Source | Independent of Staresinic 2003? | Species | Model | Endpoint category | Reported finding |
|---|---|---|---|---|---|
| Staresinic et al. 2003 | — | Rat | Achilles tendon transection, in vivo | Tendon healing (functional, biomechanical, macroscopic, and microscopic assessments) | Authors reported accelerated healing of the transected tendon |
| Staresinic et al. 2003 (same paper) | No | Not stated in the abstract | Tendocytes, in vitro | Cell growth | No effect alone; opposed HNE-induced growth inhibition in cultured cells |
| Chang et al. 2011 | Yes | Rat | Isolated tendon explants | Outgrowth | Authors reported promoted outgrowth from explants |
| Chang et al. 2011 | Yes | Rat | Cultured tendon fibroblasts | Migration | Authors reported increased fibroblast migration |
| Chang et al. 2011 | Yes | Rat | Cultured tendon fibroblasts under oxidative stress | Cell survival | Authors reported improved survival under oxidative stress |
| Chang et al. 2011 | Yes | Rat | Cultured tendon fibroblasts, separate viability assay | Proliferation | Authors did not report increased proliferation |
In the cell experiment, Staresinic et al. (2003) reported that BPC-157 alone had no effect on cultured-cell growth. In combinations tested with 4-hydroxynonenal (HNE), it opposed HNE’s growth-inhibiting effect. The results refer to the specific cell-culture conditions.
All rows describe animal or laboratory models. None measures a clinical outcome, and none supports a claim of clinical benefit or safety.
Chang et al. (2011) is the independent entry: a different group and a different publication. It also uses different endpoints. It doesn't repeat the Achilles transection experiment. Instead, it looks at outgrowth, migration, and survival in explant and cell-culture models.
Its proliferation row matters as much as its positive findings. In the separate viability assay, the authors did not report increased proliferation. "Cells survived better under stress" is a different result from "cells multiplied faster."
Classifying a study before you cite it
Before you use any tendon study, answer four questions in a single line:
- Species. Rat, mouse, human cells, or something else?
- Model. Whole animal, tissue explant, or cultured cells? If it's an injury model, what kind of injury?
- Endpoint. What was measured: function, mechanical strength, tissue appearance, cell growth, migration, or survival?
- Independence. Is this a different group and publication from the other evidence you're citing, or another experiment in the same paper?
A summary like "rat, cultured tendon fibroblasts, migration, independent of Staresinic 2003" prevents two common errors. The first is treating a cell-culture result as a healing result. The second is counting one paper twice.
Scope and dated regulatory context
This table is bounded on purpose. It covers two papers and the models named above. It doesn't survey the wider literature, give concentrations, or evaluate study quality beyond what each row states.
Readers following regulatory discussion may consult FDA's posted materials for the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting. Treat them as a record dated to that meeting. This page doesn't summarize those materials and makes no statement about approval status, compounding access, or any future decision.
References
- Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. PubMed record, 2003.
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. PubMed record, 2011.
- U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee.